About Sermorelin
Sermorelin is a synthetic GHRH (1-29) analogue used in endocrine research. Supplied as a lyophilized powder for laboratory investigations into physiological GH secretion mechanisms and pituitary signaling pathways in controlled experimental models. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: 99%+ (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models.
Recent research on Sermorelin: Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models.
Read Full Study on PubMedA new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
Recent research on Sermorelin: A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
Read Full Study on PubMedAdditional Studies
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Recent research on Sermorelin: Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Read on PubMedGrowth hormone - releasing hormone antagonists induce autophagy in cancer cells.
Recent research on Sermorelin: Growth hormone - releasing hormone antagonists induce autophagy in cancer cells.
Read on PubMedA novel approach for the treatment of AML, through GHRH antagonism: MIA-602.
Recent research on Sermorelin: A novel approach for the treatment of AML, through GHRH antagonism: MIA-602.
Read on PubMedGrowth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
Recent research on Sermorelin: Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
Read on PubMedAntagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.
Recent research on Sermorelin: Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.
Read on PubMedExploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Recent research on Sermorelin: Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Read on PubMedRelated Research
Purchase Sermorelin from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.